Myriad Genetics reported a strong start to 2023 with a 10% year-over-year revenue increase in Q1, driven by growth in Oncology, Women's Health, and Mental Health businesses. The company is confident in achieving profitability by Q4 2023 and sustainable 10%+ annual organic growth as it enters 2024.
First quarter testing volumes grew 21% year-over-year, excluding contributions from the SneakPeek® Early Gender DNA Test.
Hereditary cancer test volumes increased by 24% year-over-year, marking the second consecutive quarter of double-digit growth.
GeneSight® pharmacogenomics test volumes grew 31% year-over-year and 15% sequentially.
Diluted GAAP earnings per share (EPS) were $(0.67) and adjusted EPS were $(0.21) in the first quarter of 2023.
Myriad Genetics updated its fiscal year 2023 financial guidance, expecting revenue between $730 million and $750 million, and adjusted EPS between $(0.36) and $(0.24).
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance